Dear Dr. Fotouhi:

Please refer to your Supplemental New Drug Application (sNDA) dated September 29, 2009, received September 30, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tylenol 8-Hour (650 mg acetaminophen) extended-release tablets.

We acknowledge receipt of your submission dated March 26, 2010, received April 13, 2010.


This “Changes Being Effected” supplemental new drug application provides for revised labeling in accordance with the April 29, 2009 final monograph for Organ-Specific Warnings; Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

**LABELING**

Submit final printed labeling as soon as they are available, but no more than 30 days after they are printed. The final printed labeling (FPL) must be identical to the enclosed labels (Tylenol Arthritis Pain 40-count “gelcap” (representative of the 20-, 40-, and 80-count “gelcap”) carton and immediate container (bottle) labels, 2-count caplet immediate container (pouch) label, 50-count “caplet” (representative of the 24-, 50-, 68- (34 x 2-count pouch dispenser), 150-, 190-, 225-, and 290-count “caplet”) carton labels, 50-count “caplet” (representative of the 24-, 50-, 150-, 190-, 225-, and 290-count “caplet”) immediate container (bottle) labels, 100-count “caplet” immediate container (bottle) label, and the Tylenol 8-Hour 2-count “caplet” immediate container (pouch) label, 6-count “caplet” (3 x 2-count pouch) carton label, and 50-count “caplet” (representative of the 24-, 50-, 100-, and 150-count “caplet”) carton and immediate container (bottle) labels submitted March 26, 2010), and must be in the “Drug Facts” format (21
CFR 201.66), where applicable. FPL must be submitted for all the referenced count sizes. Representative labeling will not be acceptable in the FPL submission.

The final printed labeling should be submitted electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005)”. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Final Printed Labeling for approved NDA 019872/S-033.” Approval of this submission by FDA is not required before the labeling is used.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA, to CDERMedWatchSafetyAlerts@fda.hhs.gov, and to the following address:

MedWatch
Food and Drug Administration
Suite 12B-05
5600 Fishers Lane
Rockville, MD 20857

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call James Lee, Regulatory Project Manager, at (301) 796-5283.

Sincerely,

Andrea Leonard-Segal, M.D.
Director
Division of Nonprescription Clinical Evaluation
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

Enclosure: Carton and Container Labeling
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-19872</td>
<td>SUPPL-33</td>
<td>MCNEIL CONSUMER</td>
<td>TYLENOL</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ANDREA LEONARD SEGAL
05/06/2010